How to Value a Mohs Surgery Dermatology Practice in 2026

Mohs micrographic surgery practices are among the highest-valued medical specialties in the M&A market, and for good reason. A fellowship-trained Mohs surgeon performing 8-15 cases per day at $1,500-$3,000 per case generates revenue per provider that rivals orthopedic surgery — without the hospital overhead, anesthesia costs, or facility complexity. These practices print cash, and the buyer community knows it.

But valuing a Mohs-focused dermatology practice requires understanding a specific set of drivers that do not apply to general dermatology or cosmetic practices. Surgeon productivity, histotechnician staffing, fellowship-trained talent scarcity, and the clinical economics of same-day tissue processing all shape the multiple in ways that generic medical practice valuation frameworks miss entirely.

The Multiples: 8-15x EBITDA

Mohs-focused dermatology practices with strong financial profiles trade at 8-15x EBITDA, making them one of the premium segments in medical practice M&A. The wide range reflects significant variation in practice scale, surgeon count, and the mix between Mohs procedures and general/cosmetic dermatology.

At the high end — 12-15x EBITDA — you see multi-surgeon practices with 3+ fellowship-trained Mohs surgeons, an in-house histology lab staffed by certified histotechnicians, $5M+ in revenue, and a diversified referral network spanning primary care and multiple dermatology practices. These are platform-quality assets that PE firms acquire as anchors for dermatology roll-up strategies.

At 8-10x, you see solo Mohs surgeon practices with $1.5-3M in revenue, strong margins, but the fundamental risk that the entire surgical revenue depends on one fellowship-trained provider. The multiple is still strong by medical practice standards — general dermatology trades at 5-8x — because the Mohs economics are simply superior. But solo surgeon risk caps the multiple.

Practices that blend Mohs surgery with high-volume cosmetic dermatology (injectables, laser, Mohs reconstruction) can see even higher total enterprise values, because the cosmetic revenue adds a cash-pay stream that is not subject to payer reimbursement pressure. The combination of Mohs procedural volume and cosmetic cash-pay revenue is the most attractive financial profile in dermatology M&A.

Mohs Surgeon Productivity: The Revenue Engine

A fellowship-trained Mohs surgeon's daily case volume is the single most important variable in the valuation. The benchmarks I use when evaluating these practices:

• 8-10 cases per day: Solid, sustainable productivity. The surgeon operates at a steady pace with adequate time for complex multi-stage cases and closures. This range supports $1.2-2.0M in annual Mohs revenue per surgeon.
• 10-12 cases per day: High efficiency. Usually requires excellent histotechnician support for rapid tissue processing and a well-choreographed patient flow between multiple procedure rooms. Annual Mohs revenue per surgeon of $2.0-3.0M.
• 12-15 cases per day: Exceptional throughput seen in the most efficient practices. Requires a dedicated histology lab with multiple technicians processing slides in parallel, 4-6 procedure rooms, and a clinical team that operates like a surgical production line. Revenue per surgeon can exceed $3.5M annually.

The per-case economics drive these numbers. A typical Mohs case involving excision, tissue processing, margin evaluation, and same-day closure generates $1,500-$3,000 in total collections, depending on the number of stages (tissue layers examined), complexity of the closure, and payer mix. Medicare reimbursement for Mohs — which covers a significant portion of the patient population given the age demographic of skin cancer — runs approximately $800-$1,200 for the surgical portion, with additional fees for each stage and the closure. Commercial payers typically reimburse 120-180% of Medicare rates.

Buyers model surgeon productivity carefully because small differences in daily case count have outsized impacts on valuation. A surgeon averaging 10 cases per day versus 8 cases per day — just 2 additional cases — generates roughly $500K-$750K in additional annual revenue, which at practice-level margins of 30-40% adds $150K-$300K in EBITDA. At 10x EBITDA, that is $1.5-3M in additional enterprise value from two more cases per day.

Histotechnician Staffing: The Bottleneck

What separates Mohs surgery from other dermatologic procedures is the real-time tissue processing — the surgeon excises tissue, a histotechnician processes and stains frozen sections, and the surgeon reads the slides to determine if margins are clear, all while the patient waits. The speed and accuracy of the histotechnician directly governs how many cases the surgeon can complete per day.

A skilled Mohs histotechnician who can process a tissue specimen in 15-20 minutes is worth their weight in gold. Less experienced technicians taking 30-40 minutes per specimen cut the surgeon's throughput by 30-50%. The practical impact: a practice with two excellent histotechnicians processing slides in parallel can support 12-15 cases per day, while one with a single average technician may cap out at 6-8.

From a valuation perspective, histotechnician staffing is both a value driver and a risk factor. Certified Mohs histotechnicians (HT-ASCP or equivalent) are scarce — there are far fewer trained Mohs histotechs than there are Mohs surgeons, and competition for top talent is intense. A practice that has retained experienced histotechnicians for 5+ years has a genuine competitive advantage that buyers value. Conversely, a practice where the histotechnician just gave notice or where the surgeon is doing some of their own tissue processing presents an operational risk that buyers discount.

Some larger practices have invested in building their own in-house histology training programs, which creates a pipeline of qualified technicians and reduces recruitment risk. Buyers view this as a significant operational asset, and it directly supports the premium end of the multiple range.

Fellowship-Trained Surgeons: The Scarce Asset

Mohs surgery fellowship programs produce approximately 80-90 new fellowship-trained Mohs surgeons per year in the United States. That is a tiny pipeline for a procedure that is growing in demand as the population ages and skin cancer incidence increases. The scarcity of qualified Mohs surgeons is the structural factor that sustains premium valuations for these practices.

For buyers — particularly PE-backed dermatology platforms like Schweiger Dermatology, Forefront Dermatology, and U.S. Dermatology Partners — acquiring a Mohs practice is often the only practical way to add Mohs capability. Recruiting a fellowship-trained Mohs surgeon to join an existing platform is extremely competitive, with guaranteed compensation packages running $600K-$1M+ for established surgeons. Acquiring a practice where the surgeon is already embedded, productive, and committed (typically through a post-close employment agreement) is often more economical than de novo recruitment.

This dynamic is why PE firms pay premium multiples for Mohs practices. They are not just buying the revenue and the patient base — they are locking in access to a fellowship-trained surgeon who would be extremely expensive and difficult to recruit on the open market. Practices with multiple Mohs surgeons are exponentially more valuable because they represent multiple scarce human assets in a single transaction.

What Drives the Premium

Beyond the structural factors, several practice-level attributes separate 8x EBITDA Mohs practices from 15x ones:

Same-day closure capability. Practices where the Mohs surgeon performs both the excision and the reconstruction (flaps, grafts, complex closures) capture the full procedural revenue rather than referring the closure to a plastic surgeon. This can add $500-$1,500 per case in additional collections and materially improves revenue per case.

Pathology revenue. Practices that maintain their own CLIA-certified lab and bill the professional component of the histopathology reading capture additional revenue that practices sending slides to external labs do not. Lab revenue adds 10-15% to total practice collections.

Cosmetic integration. Mohs surgeons who also perform cosmetic reconstruction — scar revision, laser resurfacing post-Mohs, injectable fillers for volume restoration after excision — capture additional cash-pay revenue from the same patient base. This cross-selling is viewed extremely favorably by buyers because it demonstrates revenue diversification beyond insurance-dependent Mohs procedures.

Referral network breadth. Mohs practices that receive referrals from 50+ dermatologists and primary care physicians, with no single source exceeding 10% of case volume, present a far more durable revenue base than those dependent on 3-5 key referral relationships.

The Bottom Line

Mohs surgery practices sit at the intersection of clinical excellence, procedural efficiency, and structural scarcity — a combination that produces some of the strongest valuations in medical practice M&A. The 8-15x EBITDA range reflects real market transactions, and the practices that command the top of that range are those with multiple fellowship-trained surgeons, seasoned histotechnician teams, high daily case throughput, and diversified referral networks. For Mohs practice owners contemplating a sale, the market timing is favorable: PE-backed dermatology platforms are aggressively acquiring, the surgeon pipeline is constrained, and demand for Mohs procedures is growing with an aging population. The asset you have built is genuinely scarce, and the buyer community is pricing that scarcity into their offers.